Diabetes

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Find details on advances in the management of type 1 diabetes, utilization of CGM in primary care settings, and optimizing T2D management in older persons.

The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Type 2 diabetes and prediabetes were associated with accelerated brain aging, particularly among men and persons with poor cardiometabolic health, according to new research.

The Omnipod 5 is now the first automated insulin delivery system available for both T1D and T2D in the US.

Results of a global analysis of over 30 million cases showed significantly higher odds for suicidal ideation among adults who received semaglutide vs other medications.

Your daily dose of the clinical news you may have missed.

Experts on diabetes provide insights gleaned from the SIMPLE study and outline patient factors that inform treatment decisions.

Medha Munshi, MD, leads a comprehensive discussion on diabetes treatment practices and discusses the role of deprescribing and other treatment adjustments in older adult patients.

Continuing the discussion on a 68-year-old patient, the panel discusses the importance of follow-up and the benefits of combination therapies in older adults.

Focusing on diabetes testing and treatment practices, Conan Tu, MD, MBA, DACD, BC-ADM, presents the profile of a 68-year-old new patient who presents with symptoms in line with a family history of type 2 diabetes.

Conan Tu, MD, MBA, DACD, BC-ADM, presents a case of an 84-year-old patient with diabetes experiencing medication burden and glycemic control challenges.

Experts on diabetes define the concept of homeostenosis and describe the importance of recognizing signs of aging and adapting care to fit the needs of older adult patients.

Medha Munshi, MD, and Conan Tu, MD, MBA, DACD, BC-ADM, begin a discussion on geriatric diabetes care by providing an overview of the condition and gauging physician knowledge with polling questions.

Results of the 3-year SURMOUNT-1 study reflect the longest trial to date of tirzepatide in adults with overweight/obesity and risk for developing T2D.

Younger US veterans with PTSD and type 2 diabetes who no longer met criteria for PTSD were less likely to initiate insulin and had reduced odds of mortality.

Primary care clinicians can screen at-risk individuals for type 1 diabetes with a single autoantibody panel. It pays to test and educate early, according to this author.